Cargando…
Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy
Therapeutic application of unmodified camptothecin (CPT) is severely restricted by its extremely low water solubility and the instability of active lactone ring. In this study, a redox-sensitive CPT-OA conjugate containing the disulfide bond (CPT-SS-OA) was used to deliver the lactone-stabilized CPT...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882494/ https://www.ncbi.nlm.nih.gov/pubmed/31735094 http://dx.doi.org/10.1080/10717544.2019.1678696 |
_version_ | 1783474174393581568 |
---|---|
author | Li, Fu Huang, Zhao Chen, Huitong Yan, Lu Li, Jin Su, Yue Zhang, Qian Huang, Zhengye Zheng, Yaxin |
author_facet | Li, Fu Huang, Zhao Chen, Huitong Yan, Lu Li, Jin Su, Yue Zhang, Qian Huang, Zhengye Zheng, Yaxin |
author_sort | Li, Fu |
collection | PubMed |
description | Therapeutic application of unmodified camptothecin (CPT) is severely restricted by its extremely low water solubility and the instability of active lactone ring. In this study, a redox-sensitive CPT-OA conjugate containing the disulfide bond (CPT-SS-OA) was used to deliver the lactone-stabilized CPT for the improved antitumor efficacy. A non-sensitive CPT-OA was used as control to illuminate the role of disulfide bond. Both CPT-SS-OA and CPT-OA formulated in cremophor EL micelles (CM) displayed multiple therapeutic advantages: small diameter (∼14 nm), efficient cellular internalization, prolonged blood circulation, and favorable biodistribution. However, only CPT-SS-OA/CM achieved the superior chemotherapeutic efficacy over CPT solution in the Lewis lung carcinoma (LLC) cancer xenograft, which was ascribed to the accelerated release of the active lactone CPT responding to the elevated reductive glutathione in tumor cells. Such redox-sensitive lipophilic prodrugs represent an effective alternative strategy for the delivery of CPT in the active lactone form. This strategy can be used for other chemically unstable chemotherapeutant for the improved therapeutic efficacies. |
format | Online Article Text |
id | pubmed-6882494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-68824942019-12-09 Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy Li, Fu Huang, Zhao Chen, Huitong Yan, Lu Li, Jin Su, Yue Zhang, Qian Huang, Zhengye Zheng, Yaxin Drug Deliv Research Article Therapeutic application of unmodified camptothecin (CPT) is severely restricted by its extremely low water solubility and the instability of active lactone ring. In this study, a redox-sensitive CPT-OA conjugate containing the disulfide bond (CPT-SS-OA) was used to deliver the lactone-stabilized CPT for the improved antitumor efficacy. A non-sensitive CPT-OA was used as control to illuminate the role of disulfide bond. Both CPT-SS-OA and CPT-OA formulated in cremophor EL micelles (CM) displayed multiple therapeutic advantages: small diameter (∼14 nm), efficient cellular internalization, prolonged blood circulation, and favorable biodistribution. However, only CPT-SS-OA/CM achieved the superior chemotherapeutic efficacy over CPT solution in the Lewis lung carcinoma (LLC) cancer xenograft, which was ascribed to the accelerated release of the active lactone CPT responding to the elevated reductive glutathione in tumor cells. Such redox-sensitive lipophilic prodrugs represent an effective alternative strategy for the delivery of CPT in the active lactone form. This strategy can be used for other chemically unstable chemotherapeutant for the improved therapeutic efficacies. Taylor & Francis 2019-11-18 /pmc/articles/PMC6882494/ /pubmed/31735094 http://dx.doi.org/10.1080/10717544.2019.1678696 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Fu Huang, Zhao Chen, Huitong Yan, Lu Li, Jin Su, Yue Zhang, Qian Huang, Zhengye Zheng, Yaxin Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
title | Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
title_full | Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
title_fullStr | Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
title_full_unstemmed | Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
title_short | Redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
title_sort | redox-sensitive lipophilic prodrugs: delivering unstable chemotherapeutant for improved cancer therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882494/ https://www.ncbi.nlm.nih.gov/pubmed/31735094 http://dx.doi.org/10.1080/10717544.2019.1678696 |
work_keys_str_mv | AT lifu redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT huangzhao redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT chenhuitong redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT yanlu redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT lijin redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT suyue redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT zhangqian redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT huangzhengye redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy AT zhengyaxin redoxsensitivelipophilicprodrugsdeliveringunstablechemotherapeutantforimprovedcancertherapy |